The importance of a multidisciplinary collaborative approach to urological radiation complications is highlighted in a recent study by Ma et al. [1]. Their single-centre retrospective study adds to the existing body of knowledge, and the controversy in the field, regarding radiotherapy complications and toxicities from the urological perspective. The work provides some meaningful information about a subsection of patients presenting to one of the largest urology units in Australia. Furthermore, the study is well critiqued by the accompanying editorial that underscores many of the issues [2]. The Austin urology unit has a strong partnership in urooncology with radiation and medical oncology. Consequently it has developed considerable expertise in the management of uro-oncology complications.Nevertheless, some aspects of this study could be improved to produce more robust data. One such aspect is the number of patients included in the case series, which represented only a 6-month snapshot of patients who had a median (interquartile range) time to onset of complications of 4 (1-9) years. Furthermore, the sample represented only a small fraction of patients from one discipline rather than the entire department, which is made up of multiple disciplines including radiation oncology and medical oncology. The severe complication rates across the oncology disciplines, surgery, chemotherapy and radiotherapy are similar but they differ in their type and timing. Defining late radiotherapy complications can be difficult, particularly without radiation oncology input, including dosimetry, because they can occur years after treatment and can be confused with disease progression or other traumatic events.Notably, the urology unit represents one of the largest in the state and has a strong collaborative relationship with radiation oncology. Thus, it expertly manages radiotherapy complications from many other large centres besides the Austin centre. This would imply that the published sample was not truly reflective of the patients treated solely by the Austin Radiation Oncology Department. The editorial notes that almost two-thirds of patients were treated with standard external beam radiotherapy. It also highlights that <20% were treated with intensity-modulated radiotherapy, a superior technique that has been shown to reduce toxicity, which is further diminished with image-guided radiotherapy [2]. The Austin centre has treated all patients with prostate cancer with intensity-modulated radiotherapy and imageguided radiotherapy for more than a decade. Consequently, measures of frequency, incidence and prevalence; that is, how common the complications are, cannot be calculated because the denominator in terms of patients at risk and period of time is unknown. As late effects of radiotherapy occur over many years and radiotherapy is used frequently for pelvic malignancies, including the most common male cancer (prostate cancer), the denominator is likely to be large.Highlighting information on the fistula rates was also potentially...